Related Experiment Video

Updated: Aug 20, 2026

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results

S M Huang1, P M Harari

  • 1Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA.

Investigational New Drugs
|February 9, 2000
PubMed

Insights

Epidermal growth factor receptor (EGFR) is highly expressed in tumors, making it a promising cancer therapy target. Anti-EGFR monoclonal antibodies (mAbs) show potential in treating various cancers, alone or with chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Epidermal growth factor receptor (EGFR) plays a key role in cellular differentiation and proliferation.
  • Overexpression of EGFR is linked to aggressive malignant diseases, highlighting its therapeutic potential.
  • EGFR is frequently overexpressed in various types of tumors.

Purpose of the Study:

  • To review recent advancements in the development of anti-EGFR monoclonal antibodies (mAbs).
  • To examine the therapeutic potential of anti-EGFR mAbs in cancer treatment.
  • To explore strategies for modulating EGFR signaling pathways for cancer therapy.

Main Methods:

  • Review of current literature on anti-EGFR monoclonal antibody development.
  • Analysis of preclinical and clinical studies investigating anti-EGFR mAbs.
  • Examination of combination therapies involving anti-EGFR mAbs with chemotherapy or radiotherapy.

Main Results:

  • Anti-EGFR mAbs represent a promising strategy for cancer therapy.
  • These antibodies can target EGFR directly or modulate downstream signaling.
  • Combination therapies may enhance the efficacy of anti-EGFR mAbs.

Conclusions:

  • Anti-EGFR mAbs are a significant development in targeted cancer therapy.
  • Further research into anti-EGFR mAbs and combination strategies is warranted.
  • EGFR-targeted therapies offer a potential avenue for improving cancer treatment outcomes.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...